First participant enrolled in the clinical hepatic impairment study with Mangoral
Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia”) today announced that the first participant has been enrolled in the company’s clinical study with Mangoral in volunteers with different degrees of hepatic impairment. Results from this hepatic study could potentially enable the use also in Mangoral’s target population with impaired liver function.The overall objective of this special populations hepatic study is to assess the influence of hepatic impairment on the safety, pharmacokinetics and pharmacodynamics of the liver specific oral MRI contrast agent, Mangoral. Patients with moderate or